Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya

@inproceedings{Nyiro2015QuantifyingMD,
  title={Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya},
  author={Joyce Uchi Nyiro and Charles J Sande and Martin N. Mutunga and Patience Kerubo Kiyuka and Patrick K. Munywoki and J Anthony G Scott and David James Nokes},
  booktitle={Vaccine},
  year={2015}
}
BACKGROUND Severe respiratory syncytial virus (RSV) disease occurs predominantly in children under 6 months of age. There is no licensed RSV vaccine. Protection of young infants could be achieved by a maternal vaccine to boost titres of passively transferred protective antibodies. Data on the level and kinetics of functional RSV-specific antibody at birth and over the early infant period would inform vaccine product design. METHODS From a birth cohort study (2002-2007) in Kilifi, Kenya, 100… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
VIEW 5 EXCERPTS

Safety and immunogenicity of a Sf 9 insect cell - derived respiratory syncytial virus fusion protein nanoparticle

HY Chu, MC Steinhoff, A Magaret
  • vaccine
  • 2013